Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.43 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824131 | 0.89 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL24585209 | 0.85 | OPRM1 (0.54) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL21266983 | 0.82 | SHBG (0.44) | OPRL1OPRM1OPRK1OPRD1SHBG | |
| SCHEMBL10217125 | 0.81 | OPRL1 (0.39) | OPRL1OPRM1OPRK1OPRD1SHBG | |
| SCHEMBL24172197 | 0.81 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20756734 | 0.81 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL760258 | 0.80 | OPRM1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL9976590 | 0.80 | OPRM1 (0.50) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL10216742 | 0.80 | OPRL1 (0.45) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL10216748 | 0.80 | OPRL1 (0.45) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | OPRL1 4499/4885OPRM1 4718/4885OPRK1 2933/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | OPRL1 4611/4885OPRM1 4688/4885OPRK1 3823/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | OPRL1 4611/4885OPRM1 4688/4885OPRK1 3823/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | OPRL1 1269/4885OPRM1 991/4885OPRK1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.